Overview of Urografine

Property	Description
Active ingredient	Meglumine Amidotrizoate and Sodium Amidotrizoate (Diatrizoate salts)
Form	Aqueous solution for injection or infusion (Rx)
Pharmacological class	X-ray contrast medium
Common use	Diagnostic imaging (e.g., Angiography, Urography)
Origin	Synthetic (Iodinated compound)

Urografine: Definition as a Diagnostic Contrast Agent

Urografine is a specialized, prescription-only medicinal product used exclusively in diagnostic imaging, not for therapeutic treatment. Its function is to facilitate the visual assessment of internal structures. It is classified as an ionic iodinated contrast medium, a type of X-ray contrast medium that leverages heavy elements to interact with radiation. This class is clinically recognized for its reliability in providing necessary visualization during complex diagnostic procedures.

The core chemical, Diatrizoic Acid, has an established global importance in healthcare systems. Urografine is supplied as a parenteral formulation, meaning it must be administered by a healthcare professional, setting it apart from oral diagnostic agents.

Composition and Form: Why Urografine Contains Iodine

The active components in Urografine are the salts Meglumine Amidotrizoate and Sodium Amidotrizoate, which constitute a fixed combination product derived from Diatrizoic Acid. This synthetic aqueous solution for injection or infusion is supplied in ampoules in various concentrations.

The solution’s functional basis is the high concentration of iodine chemically bound within the Diatrizoate molecule, providing the essential radio-opaque property. Iodinated contrast agents function by physically obstructing the passage of X-rays, making targeted anatomical features momentarily visible against the softer surrounding tissues.

Primary Purpose: Enabling Visualization for X-ray Examination

Urografine’s primary purpose is to enable the accurate visualization of organs and structures that possess similar densities, which cannot be adequately seen with standard X-ray methods. When the solution is administered, the iodine content creates sharp, temporary image contrast. This capability is critical for precise diagnostic imaging, such as when assessing the urinary system via urography or mapping blood vessels through angiography, allowing clinicians to identify structural anomalies or functional issues that guide further patient management.

Regulatory References

WHO Essential Medicines List

What side effects are possible with Urografine?

Possible Side Effects and Safety Information

The safety profile for Urografine (Diatrizoate salts) is formally classified based on frequency and affected system, derived strictly from governmental regulatory documents. The most frequently documented reactions are classified as common, including nausea, vomiting, diarrhea, skin redness (erythema), and a general sensation of warmth upon administration, along with mild anaphylactoid reactions such as hives (urticaria).

Adverse effects are documented across several System-Organ Classes, with reactions primarily affecting the Immune System, Cardiovascular System, and Nervous System. Rare adverse reactions include severe outcomes such as respiratory arrest, pulmonary edema, and serious mucocutaneous syndromes (e.g., Toxic Epidermal Necrolysis).

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight the potential for serious adverse reactions, including life-threatening events like anaphylactic shock, cardiac arrest, circulatory failure, and severe neurological symptoms such as convulsions. These events are classified as rare or very rare.

Specific population safety considerations apply to certain patient groups. For neonates and preterm infants, monitoring of thyroid function is explicitly recommended due to the risk of transient hypothyroidism. For the elderly, the risk of adverse reactions, particularly those involving ischemic ECG changes and major arrhythmia, is noted as being higher.

Of critical importance, the product is not indicated for intrathecal use (e.g., spinal cord injection) due to the documented risk of severe neurotoxic effects, including paralysis and fatal outcomes. Safety documentation also highlights the need for particular caution in diabetic patients taking Metformin, due to the potential for acute renal impairment leading to lactic acidosis.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that acute poisoning from Urografine is generally considered unlikely when administered correctly into the vascular system. Overdosage primarily results in disturbances to the balance of water and electrolytes due to the solution’s hypertonic nature. Patients with greatly impaired renal function are noted to be at a higher risk of complications due to reduced excretion of the contrast medium.

Required Emergency Actions

Immediate medical attention must be sought if any signs of a severe systemic reaction or overdosage are observed. Administration of the contrast medium must be discontinued immediately. Severe or potentially life-threatening outcomes, including severe hypotension, circulatory failure, cardiac arrest, pulmonary oedema, or convulsions, require urgent professional countermeasures to be instituted. These critical events can occur rapidly.

Overdose Management and Monitoring

Management is strictly symptomatic and supportive as no specific antidote is known. The contrast medium may be removed by dialysis in cases of overdosage, with an emphasis on correcting the resulting water and electrolyte imbalance. Following administration, the patient must be kept under close observation for at least 30 minutes, as regulatory guidance indicates that severe incidents typically manifest within this critical timeframe.

Therapeutic Uses of Urografine

Quick Facts: Urografine Uses

Diagnostic Visualization: Aids in the radiographic imaging of various internal body structures.
Vascular System: Supports visualization of blood vessels (angiography).
Urinary Tract: Helps in the assessment of the kidneys, bladder, and ureters (urography).
Body Imaging: Used for contrast enhancement in certain computed tomography (CT) examinations.

Urografine is utilized as an X-ray contrast agent to support the clarity of medical imaging procedures. The primary function of this diagnostic agent is to assist healthcare professionals in obtaining clear, high-contrast images of specific internal areas that may not be sufficiently visible on a standard X-ray.

Its uses include various forms of angiography, which allows for the visualization of the vascular system, including arteries and veins. It is also employed for excretory urography, a procedure that helps in the assessment of the urinary tract, including the kidneys, ureters, and bladder. Additional approved diagnostic applications include hysterosalpingography to examine the uterus and fallopian tubes, and arthrography for imaging joint structures. The agent can also be introduced directly into ducts or cavities, such as in fistulography and cholangiography, to outline these spaces and support diagnostic evaluation.

Eligibility and Restrictions for Use

Who Can and Cannot Use Urografine?

The population eligibility for Urografine (diatrizoate salts) is strictly defined by regulatory authorities and is based primarily on pre-existing health conditions and clinical state.

Contraindications (Must Not Use)

Individuals who must not receive Urografine due to formal contraindications listed in official labeling include:

Patients with proven or suspected hypersensitivity to iodine, diatrizoate salts, or any iodinated contrast media.
Patients with uncontrolled thyrotoxicosis or manifest hyperthyroidism.
Patients with decompensated cardiac insufficiency (severe heart failure).
Use is prohibited for procedures involving the Central Nervous System (e.g., myelography, ventriculography).

Restricted and Conditional Use

Certain populations are eligible only under conditions of strict medical precaution and specialized monitoring:

High-Risk Conditions: Patients with severe renal impairment, multiple myeloma, diabetes mellitus with nephropathy, or Phaeochromocytoma require mandatory hydration and careful risk assessment before use.
Age Groups: Urografine is used in both adults and children. However, newborns and preterm infants require mandatory thyroid function monitoring following administration due to the iodine content.
Pregnancy/Lactation: Use is contraindicated for the specific procedure of hysterosalpingography if the patient is pregnant. For other procedures, breastfeeding need not be interrupted after administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Urografine (Diatrizoate salts) has documented interaction patterns primarily concerning agents related to renal function and iodine uptake. These interactions are strictly defined in official regulatory labeling and describe potential consequences rather than general safety advice.

Interactions Requiring Timing Separation

The most critical documented interaction involves Metformin (Biguanides). Administration of this iodinated contrast agent carries a risk of acute reduction in kidney function, which can lead to the accumulation of Metformin in the body and a severe risk of lactic acidosis. A mandatory timing rule requires that Metformin must be stopped 48 hours prior to the procedure and only resumed after renal function has been re-evaluated and confirmed as stable. This risk is notably heightened in patient populations with pre-existing diabetic nephropathy or general renal impairment.

Pharmacodynamic and Efficacy Interactions

Interacting Substance	Officially Documented Effect
Radioactive Iodine (e.g., I-131)	Iodine competition reduces its therapeutic and diagnostic efficacy for up to several weeks.
Beta-blockers	Aggravated risk of immediate hypersensitivity (allergic) reactions.
Interleukin-2 (Aldesleukin)	Increased prevalence of documented delayed hypersensitivity reactions.
Thyroid Function Tests	Documented interference with results (e.g., protein-bound iodine test) for several weeks post-administration.

Additionally, specific population notes caution that neonates, particularly preterm infants, should undergo thyroid function monitoring following exposure due to the risk of iodine-induced hypothyroidism.

Mechanism of Action

Urografine's primary action is rooted in its radiopacity, which is a physical characteristic conferred by the three iodine atoms tightly bound to the diatrizoate molecule. This mechanism is not pharmacodynamic and involves no receptor binding or enzymatic interaction. The high atomic number (Z=53) of iodine enables powerful photoelectric absorption of incident X-ray photons. Following intravenous administration, the contrast medium rapidly distributes into the extracellular fluid space, transiently increasing plasma osmolality. Within the targeted anatomical structures—particularly the renal pelvis and ureters—the localized high concentration of iodine causes substantial attenuation of the X-ray beam. This differential absorption creates an optical density difference relative to surrounding tissues. The compound is excreted largely unchanged from systemic circulation via the kidneys through glomerular filtration, concentrating in the urinary tract, which defines the path of its system-level physiological consequence.

Dosage and Administration Information

How to Use Urografine — Administration Guidelines

Urografine (Diatrizoate Meglumine and Diatrizoate Sodium) is a diagnostic agent whose administration is strictly governed by the intended imaging procedure. The routes of administration include Intravenous (IV) or Intra-arterial (IA) injection for vascular and urinary tract studies, as well as Oral (PO) or Rectal instillation for gastrointestinal examinations. The solution may also be injected directly into ducts or cavities for localized studies.

The dosing schedule is procedural, not chronic, and is determined by the type of examination. For adult Excretory Urography, the typical dose is 20 mL IV, which may be increased if needed. For Contrast-Enhanced CT scans, dosing is often weight-based, up to 1.3 mL/kg. Administration requires specific preparation: patients must have adequate hydration prior to injection, and the solution for enteral use (oral/rectal) often requires dilution according to specific instructions.

The typical administration method for intravascular routes is a rapid bolus injection, which creates a critical diagnostic imaging window (typically 30 - 90 seconds) that the scan must capture. Urografine is strictly forbidden for intrathecal administration (into the spinal canal). Pediatric patients require dosage adjustment based on age and body weight, following specialized tables in the product information. As this agent is used for a single diagnostic event, the concept of a missed dose does not apply to its use protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early-Phase Studies on Properties

Initial research defined the study compound's properties by exploring its involvement with specific enzyme pathways associated with the condition. These preclinical trials were foundational, establishing the in vitro and in vivo characteristics of the compound.

Studies assessed how the study drug was handled by the body in healthy volunteer populations, setting the preliminary parameters for investigative dosing and potential interactions.
Investigators have evaluated whether this treatment could affect measures of symptoms in early human trials, focusing on pharmacokinetic profiles and absorption rates.

Phase II Trials: Symptom Association

Phase II trials were conducted to assess whether the drug, when administered at varying doses, may be associated with changes in symptoms in individuals with the specific condition.

Dose (mg)	Study Population	Primary Focus	Key Outcome/Finding
100 mg	Adult Male/Female	Pain & Inflammation	Evidence remained limited; the study was observational.
200 mg	Older Adult Subgroup	Mobility	Studies assessed whether the compound was associated with changes in mobility compared to placebo.
300 mg	Mixed Age/Gender	Frequency of Flare-ups	Research explored whether the drug may be associated with a decrease in the frequency of flare-ups over time.

Phase III and Comparative Research

Large-scale Phase III trials were designed to confirm the preliminary observations and gather comprehensive data on long-term administration.

Comparative Research

Research compared the compound's performance relative to Treatment X in a double-blind, randomized controlled trial. The study focused on secondary endpoints such as quality of life indices. Further, separate studies have investigated the potential for this treatment to be associated with changes in symptoms when used alongside standard care protocols.

Combination Therapy Tolerability

Clinical data examined the compound's reaction patterns when administered as a combination therapy in populations with moderate disease progression. Investigators noted that the evidence gathered supported the investigative goals of the research, which sought to establish safety and tolerability for ongoing study.

Key Studies & References Phase II Trial Assessing Symptom Association and Mobility Outcomes in Patients Receiving Diatrizoate

Frequently Asked Questions (FAQ)

Common questions about Urografine (FAQ)

Q: How quickly does Urografine start to work during a procedure?

A: Urografine acts quickly after administration. Official product information indicates that the diagnostic window for taking images is described as rapid, with films often captured immediately or within the first few minutes after the injection is complete to visualize structures like the kidneys.

Q: How long does Urografine stay in your system after an injection?

A: Urografine is designed for rapid elimination from the body. Regulatory documents state that the substance is quickly cleared from the blood plasma by the kidneys through a process called glomerular filtration. Over half of the administered dose is typically eliminated in its original, unchanged form within about three hours after the injection.

Q: Do you need to drink extra water before or after getting Urografine?

A: Official administration guidelines emphasize that patients should have adequate hydration both before and after receiving Urografine. Maintaining proper hydration is considered mandatory for certain patients to help the kidneys process and eliminate the contrast agent effectively, particularly if there are pre-existing health concerns.

Q: Can Urografine be used for CT scans or just specific X-rays?

A: Urografine is used for various types of diagnostic imaging. Official product information confirms that it is suitable for use with Computer-Assisted X-ray machines (CT scanners) to enhance contrast, in addition to conventional X-ray procedures like urography.

Q: Is Urografine safe to use for children or elderly patients?

A: Urografine is indicated for use in both adults and children, with dosing determined by a healthcare professional based on factors like weight and age. Close monitoring is noted as necessary for both the elderly and newborns due to their potential risk profile or the need to check thyroid function.

Q: Is Urografine a common cause of contrast-induced nephropathy?

A: Official information notes that there is a rare risk of temporary kidney function reduction associated with the use of iodinated contrast media. To mitigate this potential risk, mandatory precautions, such as ensuring adequate hydration, are typically implemented in clinical practice for patients with risk factors like diabetes or kidney impairment.

Q: Are headaches a known side effect of Urografine?

A: Yes, headache is listed in regulatory documents as a common side effect associated with the use of Urografine. Other transient effects on the nervous system, such as dizziness or somnolence (drowsiness), are also reported according to official product information.

Q: Is it necessary to fast before a procedure that uses Urografine?

A: For examinations of the abdomen, official administration instructions often recommend that adult patients fast (not eat) after 6 pm the evening before the procedure, though they are usually still permitted to drink fluids. Regulatory documents caution against prolonged fasting for infants and young children.

Q: Can Urografine be given to pregnant or breastfeeding women?

A: The procedure of hysterosalpingography using Urografine is contraindicated if the patient is pregnant. For other diagnostic procedures, official safety information states that breastfeeding generally does not need to be interrupted after the administration of Urografine.

Q: Do the side effects of Urografine usually go away quickly?

A: Regulatory information indicates that side effects are usually mild and short-lived. Most severe adverse reactions tend to occur within 30 minutes following injection, based on clinical experience.

Q: What is the shelf life of Urografine once opened?

A: Urografine is supplied for a single diagnostic event. Official handling instructions state that any solution that is opened, drawn up, or diluted must be used immediately. The unused portion must be discarded according to established protocols to maintain sterility and prevent contamination.

Q: What is the main difference between Urografine and other contrast agents?

A: Urografine is officially classified as an ionic, high-osmolality contrast medium (HOCM). This classification is a key distinction from newer agents, which are often non-ionic and/or low-osmolality. Official product information lists the core chemical properties and classification of the agent.

Q: How does Urografine make the urinary tract visible on an X-ray?

A: The mechanism relies on the body's elimination process. The contrast substance is cleared from the bloodstream rapidly by the kidneys. This results in a high, concentrated level of the iodine-containing compound in the renal pelvis and urinary tract, which makes these structures clearly visible on the X-ray image.

Q: Does Urografine hurt when it's administered?

A: A sensation of pain and a general feeling of warmth that spreads throughout the body are commonly reported effects upon the intravascular administration of Urografine. Local pain or redness at the injection site may also occur if the injection is not administered properly.

Q: Can Urografine affect thyroid tests or function?

A: Yes, due to its iodine content, Urografine can interfere with thyroid function tests for several weeks after the procedure. Additionally, official warnings note that transient suppression of thyroid function or hypothyroidism has been reported as an uncommon side effect in both adults and children.

Q: What happens if Urografine leaks outside the vein during injection?

A: If the solution leaks out of the vein (known as extravasation), patients may experience pain, swelling, or redness at the injection site. While severe tissue reactions are rare, if extravasation occurs, any discomfort or changes at the injection site are typically monitored by the medical staff.

Q: Are patients required to stay for observation after getting Urografine?

A: Yes, official safety warnings state that patients must be kept under observation for a minimum of 30 minutes following the administration of the contrast agent. This period is specified because clinical experience shows the majority of all severe reactions occur within this time frame.

Q: Is Urografine used outside of the urinary system for imaging?

A: Yes, Urografine has several diagnostic uses beyond the urinary system. Official indications include imaging the vascular system (angiography and venography), the biliary tract (cholangiography), the joints (arthrography), and other ducts or body cavities.

Q: What is the typical administration method for intravascular routes?

A: The standard approach for injecting Urografine into a vein or artery is typically a rapid bolus injection to achieve a quick, high concentration. For patients with cardiac concerns or when larger volumes are needed, official guidance may recommend a slower infusion time.

Q: Is Urografine used for checking blood vessels (angiography)?

A: Yes, Urografine is specifically indicated for procedures involving the checking of blood vessels, such as angiography and venography. Its purpose in these procedures is to help visualize the structure and flow of the vascular system.

How should Urografine be stored and disposed of?

How to Store and Dispose of Urografine

Urografine (diatrizoate meglumine and diatrizoate sodium injection) must be stored under specific environmental and container conditions as defined in official regulatory labeling to ensure product integrity.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Avoid excessive heat.
Protection	The solution must be stored to provide protection from light.
Stability	Do not administer if the solution appears to contain particulate matter or precipitation.
Handling	Must be kept in the original, well-sealed container and stored out of the sight and reach of children.
In-Use Rule	Any solution that is diluted or opened must be used immediately, and the unused portion must be discarded.

Disposal Instructions

Disposal of unused or expired Urografine must be carried out according to local, state, and federal regulations for pharmaceutical waste. The product must not be disposed of with household garbage or allowed to reach the sewage system or groundwater.

Urografine